Monoclonal gammopathy
MONDO:0004960A condition characterized by the abnormal presence of monoclonal immunoglobulins in the blood or urine.
98 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New antibody could clear toxic proteins from organs in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in 125 people with a rare disease called AL amyloidosis, where abnormal proteins build up in organs like the heart and kidneys. The drug is designed to remove those protein deposits. The goal is to see if it helps people live …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aims to clear amyloid clumps and save hearts
Disease control OngoingThis phase 3 trial tests whether CAEL-101, an antibody that removes abnormal protein deposits from organs, can help people with AL amyloidosis live longer and avoid heart-related hospital stays. About 281 participants who have not yet received treatment for their plasma cell diso…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…
Phase: PHASE1, PHASE2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to ease nerve pain in rare blood disorder
Disease control OngoingThis phase 2 trial tests whether the drug zanubrutinib, combined with standard rituximab, can improve nerve damage and disability in people with a rare blood condition called IgM MGUS. The study includes 35 adults across two Dutch hospitals. Participants take zanubrutinib daily f…
Phase: PHASE2 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug aims to stop transplant attack on the body
Disease control OngoingThis phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 ad…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a cancer drug stop myeloma before it starts?
Disease control OngoingThis phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Phase: PHASE2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo therapy targets nerve pain in rare blood cancers
Disease control OngoingThis study tests whether combining acalabrutinib with rituximab is safe and effective for people with nerve damage (neuropathy) linked to two blood conditions: IgM MGUS or Waldenstrom macroglobulinemia. The main goal is to see if the treatment lowers a key protein (IgM) in the bl…
Phase: PHASE2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Promising nerve pain drug trial for MGUS patients withdrawn before start
Disease control TerminatedThis study aimed to test if daratumumab could improve nerve damage (peripheral neuropathy) in people with a blood condition called MGUS. Participants would have received weekly injections for two months, then biweekly for four more months. However, the trial was withdrawn before …
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New blood test screening targets hidden cancer in black communities
Diagnosis OngoingThis study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Tho…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Old diabetes drug, new hope: could metformin stop myeloma before it starts?
Prevention OngoingThis phase 2 trial is testing whether metformin, a widely used diabetes medication, can prevent progression to multiple myeloma in 60 people with early blood disorders called MGUS and smoldering multiple myeloma. Participants receive either extended-release metformin or a placebo…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 09:03 UTC
-
Could a Plant-Based diet stop a blood cancer before it starts?
Prevention OngoingThis study tests whether a plant-based diet is practical for overweight people with MGUS or smoldering multiple myeloma, conditions that can lead to multiple myeloma. For 12 weeks, 23 participants receive two pre-made plant-based meals daily. Researchers track weight loss and die…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Jun 26, 2026 15:05 UTC
-
Laser light shows promise for rare nerve pain
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether photobiomodulation (low-level laser therapy) can reduce pain and disability in people with anti-MAG neuropathy, a rare nerve condition. Ten participants will receive 16 laser sessions over six weeks. Researchers will measure changes in disability, pain, a…
Sponsor: Centre Hospitalier de Cornouaille • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could listening to music ease the stress of stem cell transplants?
Symptom relief OngoingThis pilot study tests whether a daily mindful music listening program is practical and acceptable for patients hospitalized after an allogeneic stem cell transplant. About 35 adults will listen to music for one hour each day using a web-based platform. The study measures how fea…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Art and exercise may boost recovery for kids after transplant
Symptom relief OngoingThis study looks at whether adding art therapy to physical therapy can help children aged 5 to 18 recover emotionally and physically after a stem cell transplant. For two weeks, some children receive both art and physical therapy daily, while others get only physical therapy. Res…
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Did storing testicular tissue as a child protect fertility? new study aims to find out
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 50 young men who had cancer or blood disorders as children and received treatments that can harm fertility. Some stored testicular tissue before treatment; others did not. Researchers will check their fertility through exams, ultrasounds, blood tests, and semen…
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists launch tissue bank to unlock secrets of rare blood cancers
Knowledge-focused OngoingThis study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers, how they pr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive MGUS screening aims to unlock early myeloma clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study screens 1000 adults aged 40 and older for MGUS, a condition with an abnormal blood protein that can sometimes lead to multiple myeloma. Researchers want to learn about genetic and immune factors behind MGUS, especially in diverse populations. The goal is to improve ear…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Scientists track nutrient use in bone marrow cells to understand Pre-Cancer
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a new lab method to see how certain bone marrow cells take up nutrients like glucose and amino acids. Researchers will compare cells from people with a pre-cancer condition called MGUS to cells from healthy volunteers. The goal is to better understand the disease…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Iceland launches massive screening study for early cancer detection
Knowledge-focused OngoingThis study is screening over 80,000 people in Iceland to see if early detection of a condition called MGUS can prevent or improve outcomes for multiple myeloma, a type of blood cancer. Participants are randomly assigned to routine care or closer monitoring. The goal is to compare…
Phase: NA • Sponsor: University of Iceland • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC